EUVIMEDEUVIMED entdecken
Crossref

Beyond the Label: Real-World Side Effects Experienced With FDA-Approved Drugs for Non-Melanoma Skin Cancers

Advaitaa Ravipati, Tejus Pradeep, Keyvan Nouri

Journal of Drugs in Dermatology · 2024

DOI: 10.36849/jdd.7968 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Drugs in Dermatology, 2024. Verfasst von Advaitaa Ravipati und 2 weiteren Autor:innen. Hauptthemen laut MEDLINE: Skin Neoplasms, United States Food and Drug Administration, Drug Approval.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Skin NeoplasmsUnited States Food and Drug AdministrationDrug ApprovalHumansMaleFemaleUnited StatesMiddle AgedAgedPyridinesAnilidesBasal Cell CarcinomaImmune Checkpoint InhibitorsAdverse Drug Reaction Reporting SystemsAlopeciaAdultAntibodies, Monoclonal, HumanizedCarcinoma, Squamous Cell

Substanzen

PyridinesAnilidesHhAntag691Immune Checkpoint InhibitorsAntibodies, Monoclonal, Humanized

Zitieren

APA

Ravipati, A., Pradeep, T., & Nouri, K. (2024). Beyond the Label: Real-World Side Effects Experienced With FDA-Approved Drugs for Non-Melanoma Skin Cancers. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.7968

Vancouver

Ravipati A, Pradeep T, Nouri K. Beyond the Label: Real-World Side Effects Experienced With FDA-Approved Drugs for Non-Melanoma Skin Cancers. Journal of Drugs in Dermatology. 2024. doi:10.36849/jdd.7968

BibTeX
@article{Ravipati2024,
  author = {Ravipati, Advaitaa and Pradeep, Tejus and Nouri, Keyvan},
  title = {Beyond the Label: Real-World Side Effects Experienced With FDA-Approved Drugs for Non-Melanoma Skin Cancers},
  journal = {Journal of Drugs in Dermatology},
  year = {2024},
  doi = {10.36849/jdd.7968}
}
Kostenlos starten →